Remove 2030 Remove Labelling Remove Pharmaceutical Companies
article thumbnail

Eli Lilly achieving significant gains in obesity results

Pharmaceutical Technology

Eli Lilly has achieved significant gains in the past quarter, leading to it becoming the most valuable pharmaceutical company in the world, with a market cap of $420bn, surpassing Johnson & Johnson. There have been several Phase III trials for Mounjaro, with SURMOUNT-1 demonstrating a weight loss of up to 22.5%

article thumbnail

Novo Nordisk Invested EUR 2.1 Billion in a French Manufacturing Site to Meet Growing Demand for Diabetes and Obesity Therapies

Roots Analysis

The government acknowledges the strategic importance of such investments in bolstering the country’s standing in the global pharmaceutical landscape. To address this, the company has taken measures such as restricting access to lower starting doses of Ozempic in the European Union and the United States.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Meet the 2023 Social Impact Category Winner: Takeda SA

ISPE

Takeda is the first pharmaceutical company worldwide to have implemented this water preservation project, in collaboration with a Belgian start-up Ekopak, on a large scale. By 2026, the site will produce 80% of its electricity consumed on-site and aims to be a net-zero greenhouse gas emissions site by 2030.

article thumbnail

Economist Impact: World Cancer Series – pharmaphorum in attendance, day one (part ii)

pharmaphorum

With 90% of adolescents that should be vaccinated by 2030, Luppi deems it an opportunity. We are still in a pandemic, but the World Cancer Series congress itself would not have been possible without pharmaceutical companies investing heavily in research on SARS-CoV-2. Pharma needs to continue to invest in M&D.

article thumbnail

The EU joint HTA procedure: a gate or barrier for access?

Pharmaceutical Technology

By 2030, JCAs will be carried out on all medicinal products with an EMA-issued MA. However, he did point out that the joint assessment could be a useful way of narrowing down typically broad EMA label content to specific patient populations. Will the joint procedure drive positive change?